The frequency of global crises such as hurricanes, war, and the pandemic makes a standing committee necessary.
The Community Oncology Alliance (COA) has launched a new standing Humanitarian Aid Committee, which will coordinate aid for those affected by war, natural disasters, and other crises. The group’s first effort will be supporting 4 medical charities that are assisting those affected by the war in Ukraine: Americares, Direct Relief, Doctors Without Borders, and International Medical Corps. A webpage for the committee can be found here.
A statement from COA released Monday says that although the group’s mission is based in the United States, “the greater oncology community has a responsibility to act and engage on a global scale during times of crisis.” COA has worked with other groups on hurricane relief efforts and on the global effort to keep patients safe during the COVID-19 pandemic.
The frequency of such events makes a standing committee necessary, the group said.
“Cancer isn’t localized to one country or region of the world, and it certainly doesn’t become less important during times of crisis,” said Mark Thompson, MD, COA’s medical director of public policy. “As people are displaced and seek shelter, it’s our responsibility to help them continue treatment. Cancer doesn’t stop during an emergency. COA’s mission to fight cancer doesn’t either.”
The Humanitarian Aid Committee will include both volunteers and staff. Current members include:
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More